Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

PSTV earnings analysis

Filed May 15, 2026 · Our reading of the company's report

The latest report

Plus Therapeutics reported Q1 2026 results showing revenue of $1.0 million, a decrease from $1.1 million in Q1 2025. However, the diluted EPS improved significantly to -$1.05 from -$29.86 in the same quarter last year.…

Read full summary

Plus Therapeutics reported Q1 2026 results showing revenue of $1.0 million, a decrease from $1.1 million in Q1 2025. However, the diluted EPS improved significantly to -$1.05 from -$29.86 in the same quarter last year. The company completed a public offering generating $15 million, increasing cash balances to a total of $3.0 million by the end of the quarter.

Read the original on SEC.gov

Reported figures

Earnings per share
$-1.05

What stood out

  • Stable Revenue Figures

    Reported revenue for Q1 2026 was $1.0 million, unchanged from Q4 2025 but down from $1.1 million in Q1 2025.

  • Significant EPS Improvement

    Diluted EPS for Q1 2026 improved to -$1.05, significantly better than -$29.86 in Q1 2025.

  • Cash Surplus Boost

    Completed a public offering that raised $15 million, bringing cash equivalents to $3.0 million.

  • Increased R&D Spending

    Research and development expenses surged to $2.86 million from $1.75 million in the same period last year.

  • Operating Loss Reduced

    The operating loss was $6.9 million for Q1 2026, less than the prior year loss of $14.1 million.

  • Significant Equipment Investments

    Invested $8.5 million in capital expenditures during the quarter.

What to watch

  • Rising Operational Costs

    R&D costs spiked by approximately $1.1 million compared to the same period last year, reflecting ongoing development challenges.

  • Cash Flow Concerns

    Net cash used in operating activities reached $6.2 million, a concerning trend as the company continues to burn cash.

  • Dependence on External Funding

    Dependence on future financings increases risk, as the company acknowledges ongoing needs to raise capital.

Management's outlook

No specific financial guidance disclosed; management indicates growth in diagnostic revenue expected in 2026.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.